August 2025 in “MedScien” Tumor-targeted drug carriers can improve chemotherapy precision and reduce side effects.
January 2026 in “Case Reports in Rheumatology” Rituximab improved her dermatomyositis better than usual treatments.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
July 2024 in “Reactions Weekly” 7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
Biorregulatory therapy significantly improved the dog's health, reversing previous issues and eliminating the need for ongoing medication.
ETS2 is crucial in squamous cell carcinoma development and could be a therapeutic target.
May 2010 in “OPAL (Open@LaTrobe) (La Trobe University)” Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.
4 citations
,
October 2019 in “Skin Appendage Disorders” Gefitinib can cause hair and eyebrow darkening.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
4 citations
,
February 2018 in “World journal of surgical oncology” A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
May 2025 in “Dermatology Online Journal” Erlotinib can cause excessive eyelash growth.
7 citations
,
July 2013 in “Acta Biochimica Polonica” Chemotherapy reduces splenic melanin in mice.
January 2025 in “Cell Communication and Signaling” CXXC5 can both suppress and promote cancer, making it a complex target for treatment.
April 2026 in “UNC Libraries” Pulsed electric field treatment may help shrink untreated liver tumors.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
1 citations
,
November 2025 in “Journal of the American Academy of Dermatology” 28 citations
,
February 2007 in “Cancer Research” Blocking certain proteins in mouse skin can reduce and shrink skin tumors.
13 citations
,
August 2018 in “Life sciences” Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.
8 citations
,
January 1977 in “Acta Haematologica” The treatment was effective for advanced non-Hodgkin's lymphomas.
May 2026 in “Journal of Clinical Oncology” Later line chemotherapy causes severe side effects, impacting quality of life, but patients continue treatment to extend life and stay connected with loved ones.
3 citations
,
July 2019 in “Supportive Care in Cancer” The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
May 2015 in “Cancer research” After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.
75 citations
,
June 2007 in “Journal of Biological Chemistry” MT-DADMe-ImmA can selectively kill head and neck cancer cells without harming normal cells.
2 citations
,
March 2010 in “Acta Biochimica Polonica” Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.
7 citations
,
March 2023 in “Lasers in Surgery and Medicine” Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
November 2005 in “Reactions Weekly” A man treated with gefitinib for lung cancer grew new hair on his bald scalp.
70 citations
,
December 2008 in “Cancer Research” CXCR2 in skin cells promotes tumor growth.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.